PEDAL:  Parkinson’s Environment, Diet and Lifestyle Study and Registry

Who Qualifies for This Research Study?  The people who may qualify for this study:

  • Diagnosed by a physician with Parkinson’s disease
  • Aged 18 years or older
  • Current resident of MN

What is the Purpose of this Clinical Research Study?

The University of Minnesota’s School of Public Health is working on create a state-wide voluntary registry of Minnesotans with Parkinson’s disease (PD) who are interested in PD research. The current research project, the PEDAL Study, focuses on potential causes of PD. Specifically, the study will determine if environmental exposures to pesticides and minerals such as manganese increase the risk of PD along with some genetic causes. This research will enhance knowledge of the connections between food and water exposures and other environmental factors with occurrence of PD in Minnesotans. PEDAL will also be a resource for other PD researchers, so physicians and public health works can better select and develop therapies, protect from or reduce the risk of PD in others, and plan for future care in Minnesota.

PEDAL Study participants are able to do all aspects of the study from their own homes and receive a $10 gift card upon completing the study. To date, about 300 Minnesotans with PD have become involved with this research.

Act now and join the PEDAL Study! Contact the study office for more information!

PEDAL Study & Registry
Health Studies
School of Public Health
University of Minnesota Tel: 1-800-825-2227    E-Mail: um-pedal@umn.edu

 

PD “OFF”  Study

Who Qualifies for this Research Study?   The people who may qualify for this study:

  • Be 18 years of age or older
  • Have a medical diagnosis of Parkinson’s disease
  • Be receiving stable doses of levodopa/ carbidopa or Rytary™
  • Experience at least one “OFF” state per day, with a daily total of 2 or more “OFF” hours during the day
What is the Purpose of the Clinical Research Study?
Due to the frequency and negative impact of “OFF” states in people with Parkinson’s disease, patients need a medication that can rapidly and reliably reverse their “OFF” state in a more convenient way. The only approved drug to address this issue requires an injection, and this Investigational drug is looking to see if a more convenient version of the medication can solve this problem. Therefore, it’s important to research and evaluate additional treatment options that may offer quick and effective relief from “OFF” states, while being easy to administer. The results of this study will provide more information about the safety and effectiveness of the investigational drug. By taking part in this study, you will be making an important contribution to “OFF” state treatment research in Parkinson’s disease patients.
Brochure       Poster

Potential volunteers can also contact the site directly if they wish.

Dr. Sotirios Parashos
Park Nicollet Institute – Struthers Parkinson’s Center
6701 Country Club Dr.
Golden Valley MN 55427

Contact: Sadie McGregor
sadie.mcgregor@parknicollet.com
(952) 993-5903

 

PD Yoga Study
Who Qualifies for This Research Study?  The people who may qualify for this study:

  • If you have been diagnosed with Parkinson’s disease
  • Between the ages of 45-75
  • On optimized dopaminergic therapy
  • Not regularly practicing any supervised exercise, this may be the study for you.

Researchers at the University of Minnesota are currently conducting a study to assess the effect of yoga on Parkinson’s.
Please call 612-626-8970 or e-mail us at pdyoga@umn.edu for more information.

Click here to learn more!

 

Sense of Wrist Position Study
Who Qualifies for This Research Study?  The people who may qualify for this study:

  • Diagnosed with Parkinson’s disease
  • Adults 18 years of age or older
  • No other known neurological disorders

What is the Purpose of this Clinical Research Study?  Click here for the flyer
View consent form for more information

 

Movement Initiation Study
Who Qualifies for This Research Study?  The people who may qualify for this study:

  • Have been diagnosed with Parkinson’s Disease
  • If you are from 21 to 75 years of age

What is the Purpose of this Clinical Research Study?

We invite you to contact the University of Minnesota with your interest in the study. Participants are eligible to receive compensation of $150 for your time and inconvenience during participation in the study. You will also be reimbursed for all of your travel expenses.

This study is being conducted by faculty in the Departments of Neurology and Kinesiology at the University of Minnesota and is sponsored by the National Institutes of Health.

If you are interested in learning more about the study or want to find out if you qualify for participation, please call or email:

Joshua de Kam
Research Coordinator
Department of Neurology
University of Minnesota
Tel: (612) 626-8052
E-Mail: jadekam@umn.edu

 

Sleep and Movement in Parkinson’s disease

Who Qualifies for This Research Study?  The people who may qualify for this study:

  • Have been diagnosed with Parkinson’s disease
  • If you are between 21 and 75 years old

What is the Purpose of this Clinical Research Study?

Seeking volunteers to participate in a research study examing the relationship between sleep disturbances and the development of movement problems in people with Parkinson’s disease.

Click here for the flier.

 

BioFIND Research study

Who Qualifies for This Research Study?  The people who may qualify for this study:

  • Men and women over 55 years old who have had PD for at least five years
  • The study seeks  as well as control volunteers who do not have PD or a first-degree blood relative with PD.

What is the Purpose of this Clinical Research Study?

The University of Minnesota is a clinical site for BioFIND, a multi-site study exclusively focused on discovering new Parkinson’s disease (PD) biomarkers. Biomarkers are critical to accelerating the development of disease-modifying therapies that can transform patients’ lives.

Currently, Parkinson’s patients only have treatments that temporarily alleviate symptoms of the disease. BioFIND seeks to discover new PD biomarkers, tools that are crucial for researchers to develop disease-modifying therapies that can slow or stop disease progression.

BioFIND can’t get started without volunteers.   The University of Minnesota is one of five study sites that are looking for these volunteers.

Those who participate in BioFIND will visit the site twice in a two-week period. On the first visit they will undergo clinical assessments and take written surveys. The second visit includes a few additional clinical tests, as well as a blood draw and a lumbar puncture. Participants’ health will be closely monitored by experienced doctors and nurses throughout the study.

Volunteers will be compensated for travel and time in the study, and their privacy will be closely guarded. Most importantly, they will have the personal satisfaction of being part of a study that could help speed a cure for Parkinson’s disease.

BioFIND is sponsored by The Michael J. Fox Foundation for Parkinson’s Research and funded in part by The National Institute of Neurological Disorders and Stroke.

For more information about BioFIND at the University of Minnesota, contact the Clinical Neuroscience Research Unit at 612.624.7745 or cnru@umn.edu.

 

Clinical Reseach in Fargo

Who Qualifies for This Research Study?  The people who may qualify for this study:

  • Are 30-85 years old
  • Have been taking levodopa (L-dopa) medication for Parkinson’s disease for 1 year or longer
  • Have been experiencing motor fluctuations (medication “off” time) for at least the last month, with or without jerky, dance-like movements of the arms and/or head (dyskinesia)
  • Do not have uncontrolled high blood pressure, cardiovascular disease or any other significant neurological or psychiatric disorder

SanfordHealth in Fargo is conducting a research study to test an investigational medication aimed at improving the symptoms of patients with moderate to severe Parkinson’s disease.  The clinic has 200 patients enrolled and need a total of 450 patients with moderate-to-severe Parkinson’s disease to participate in this study.

What is the Purpose of this Clinical Research Study? This study will test the safety and effectiveness of an investigational medication when it is used together with levodopa (L-dopa) for people with moderate to severe Parkinson’s disease. Different dose levels of the study medication will be compared to placebo (looks like the investigational medication but does not contain the active ingredient) when added to L-dopa.

Parkinson’s disease affects an estimated four to six million people and their families all over the world. A brochure about the clinical trial is here.